iTeos Therapeutics stock (US46572C1009): focus shifts to anti-TIGIT data after Galapagos deal collapse

Immuno-oncology specialist iTeos Therapeutics has been back in the spotlight after Roche ended their TIGIT partnership and a Phase 1b/2 trial update in lung cancer. What the latest clinical data and cash position mean for the Nasdaq-listed biotech.

iTeos Therapeutics has come back into focus for biotech investors after a series of developments around its lead anti-TIGIT antibody and a reshaping of its partnership landscape. The biotech reported updated results from an early-stage trial of its immunotherapy combinations in non-small cell lung cancer in late 2024, while Roche terminated its co-development deal for the TIGIT candidate in 2024, forcing iTeos to reassess its strategy, according to iTeos investor update as of 06/06/2024 and Reuters as of 06/06/2024.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: ITOS
• Sector/industry: Biotechnology, immuno-oncology
• Headquarters/country: Watertown, Massachusetts, United States
• Core markets: Oncology drug development with a focus on solid tumors
• Key revenue drivers: Collaboration income and potential future milestone and royalty streams
• Home exchange/listing venue: Nasdaq (ticker: ITOS)
• Trading currency: USD

iTeos Therapeutics: core business model

iTeos Therapeutics focuses on discovering and developing cancer immunotherapies that aim to enhance the body’s immune response against tumors. The company is best known for targeting immune checkpoint pathways, including TIGIT and PD-1, which play a key role in the balance between immune activation and tolerance in oncology, according to iTeos pipeline overview as of 03/01/2025.

The biotech’s lead asset is the anti-TIGIT monoclonal antibody EOS-448, which is designed to block an inhibitory receptor on T cells and natural killer cells. By interfering with TIGIT signaling, EOS-448 is intended to restore or enhance antitumor immunity when administered alone or in combination with other checkpoint inhibitors. This mechanism has attracted considerable interest across big pharma in recent years, although clinical outcomes across the class have been mixed.

Beyond EOS-448, iTeos is also advancing inupadenant, an A2A receptor antagonist, which is aimed at modulating adenosine signaling in the tumor microenvironment. Adenosine can suppress immune cell activity, and blocking its receptor may help promote a more active immune response. These assets are being evaluated both as monotherapies and in combination regimens, aiming to identify patient subgroups and indications where the biology translates into meaningful clinical benefit.

The company’s business model reflects the typical profile of a clinical-stage biotech with no approved products. iTeos invests heavily in research and development and funds its operations primarily through equity raises, partnerships, and milestone payments. Collaboration agreements with larger pharmaceutical companies have historically provided non-dilutive capital, though the termination of the Roche collaboration has shifted expectations for future external funding, according to iTeos Q2 2024 earnings presentation as of 08/08/2024.

Main revenue and product drivers for iTeos Therapeutics

As a development-stage company, iTeos currently generates limited revenue, primarily from collaboration income recognized under existing and past alliances. In its financial report for the second quarter of 2024, the company reported collaboration revenue of a low-double-digit million US dollar amount for the period, while net losses reflected ongoing investment in clinical trials and discovery programs, according to iTeos Q2 2024 financial results as of 08/08/2024.

The medium- to long-term revenue potential for iTeos hinges on successful clinical development and regulatory approval of its lead candidates. EOS-448 is being evaluated in combination with various agents, including PD-1 inhibitors, in tumor types such as non-small cell lung cancer and head and neck cancer. Positive efficacy signals in these settings could support future registrational studies and, if successful, eventual commercialization either independently or through new partnerships.

In addition, inupadenant’s progress will be closely watched as a potential differentiator in the crowded immuno-oncology landscape. Adenosine pathway modulation has seen interest from several competitors, and iTeos’ ability to show durable responses or synergy with other immunotherapies could influence its future negotiating power with larger pharma partners. For investors, the key drivers are the strength of clinical data, the speed of trial enrollment, and the level of cash burn required to reach critical inflection points in the pipeline.

From a financial perspective, iTeos has emphasized its cash position as a strategic asset. The company reported a substantial cash, cash equivalents, and marketable securities balance at the end of June 2024, which management said would finance operations into 2026, according to the same second-quarter 2024 report. This runway provides time to deliver several meaningful clinical updates without immediate pressure to raise additional capital in a volatile biotech funding environment.

Conclusion

iTeos Therapeutics occupies a high-risk, high-uncertainty niche within the immuno-oncology segment, with its valuation and share price closely tied to clinical readouts and partnership dynamics. The end of the Roche collaboration in 2024 removed a major external validation point but also gave the company full control over its anti-TIGIT asset and future deal options. At the same time, a solid cash position and ongoing early-stage data updates provide room for iTeos to refine its development strategy and potentially re-engage with partners. For US-focused investors following Nasdaq-listed biotech names, the stock represents an example of how rapidly sentiment can shift in response to trial outcomes and strategic decisions, underscoring the need to monitor both scientific progress and funding visibility.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.